Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860157 | 0.88 | GAA (0.37) | ALDH1A1KDM4ENPC1MAPTNPBWR1 | |
| SCHEMBL5860179 | 0.83 | MEN1 (0.39) | ALDH1A1KDM4EMAPTCYP2D6CYP1A2 | |
| SCHEMBL5862720 | 0.79 | MMP8 (0.45) | ALDH1A1KDM4ENPC1MAPTNPBWR1 | |
| SCHEMBL5860590 | 0.75 | KDM4E (0.39) | ALDH1A1KDM4EMAPTTSHRCYP2D6 | |
| SCHEMBL7004971 | 0.75 | ELANE (0.38) | ALDH1A1TSHRCYP2D6LMNACYP1A2 | |
| SCHEMBL29299764 | 0.74 | MAPT (0.56) | ALDH1A1KDM4EMAPTRAB9ACYP2D6 | |
| SCHEMBL5861779 | 0.73 | GAA (0.47) | ALDH1A1KDM4EMAPTTSHRLMNA | |
| SCHEMBL9570492 | 0.73 | MAPT (0.39) | ALDH1A1NPC1MAPTNPBWR1RAB9A | |
| SCHEMBL2310025 | 0.72 | LMNA (0.62) | ALDH1A1NPC1TSHRMMP8CYP2D6 | |
| SCHEMBL9146625 | 0.72 | MEN1 (0.33) | ALDH1A1LMNAMEN1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153034-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2007-10-17 | — | — | EP | disclosed |
| US-6992097-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050143318-A1 | Growth hormone secretagogues | DODGE JEFFREY A (US) | 2005-06-30 | — | — | US | disclosed |
| US-6828331-B1 | Non-peptidyl in nature and are, therefore, more metabolically stable than growth hormone, growth hormone releasing hormone, or analogs of either of these proteins | ELI LILLY AND COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20040122234-A1 | Growth Hormone secretagogues | HAUSER KENNETH LEE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6639076-B1 | Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1112071-A4 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6329342-B1 | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1153034-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1112071-A1 | GROWTH HORMONE SECRETAGOGUES | Eli Lilly & Company (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000049037-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000010565-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0933365-A2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0898963-A2 | Congestive heart failure treatment | ELI LILLY AND COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| WO-1999008697-A1 | TREATMENT OF CONGESTIVE HEART FAILURE WITH GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999008699-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143318-A1 | Growth hormone secretagogues | GHSR, GHRHR, SSTR3 | ALDH1A1 4506/4885KDM4E 3442/4885NPC1 2703/4885 |
| US-20040122234-A1 | Growth Hormone secretagogues | GHSR, GHRHR, CRH | ALDH1A1 4382/4885KDM4E 3260/4885NPC1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.